BBOT

BridgeBio Oncology Therapeutics, Inc. Common Stock
BBOT

Overview Fund Activity

31 hedge funds and large institutions have $171M invested in BridgeBio Oncology Therapeutics, Inc. Common Stock in 2024 Q3 according to their latest regulatory filings, with 2 funds opening new positions, 4 increasing their positions, 3 reducing their positions, and 2 closing their positions.

New
Increased
Maintained
Reduced
Closed
Holders
31
Holders Change
–
Holders Change %
0%
% of All Funds
0.45%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
2
Increased
4
Reduced
3
Closed
2
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

1
SSA
1
Schonfeld Strategic Advisors
New York
$1.25M
2
SCM
2
Silverarc Capital Management
Massachusetts
$5.36M
3
Millennium Management
3
Millennium Management
New York
$11.8M
4
ACP
4
Acuta Capital Partners
California
$1.89M
5
Citadel Advisors
5
Citadel Advisors
Florida
$13.9M

Top Sellers

1
Walleye Capital
1
Walleye Capital
New York
$0
2
Walleye Trading
2
Walleye Trading
New York
$0
3
CAC
3
Cowen and Company
New York
$471K
4
T. Rowe Price Associates
4
T. Rowe Price Associates
Maryland
$11.8M
5
T. Rowe Price Investment Management
5
T. Rowe Price Investment Management
Maryland
$4.16M
Name Holding Trade Value Shares
Change 		Shares
Change %
WP
26
Woodline Partners
California
$1.08M – – –
MCM
27
Moore Capital Management
New York
$1.05M – – –
CAC
28
Cowen and Company
New York
$471K -$57.1K -5,463 -11%
Geode Capital Management
29
Geode Capital Management
Massachusetts
$114K – – –
UBS Group
30
UBS Group
Switzerland
$219 +$219 +21 New
JPMorgan Chase & Co
31
JPMorgan Chase & Co
New York
$42 – – –
Walleye Capital
32
Walleye Capital
New York
– -$949K -92,864 Closed
Walleye Trading
33
Walleye Trading
New York
– -$534K -52,236 Closed
1
2